The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform

Tsukasa Baba - One of the best experts on this subject based on the ideXlab platform.

  • salvage chemotherapy with taxane and platinum for women with recurrent uterine Carcinosarcoma
    Gynecologic Oncology, 2017
    Co-Authors: Koji Matsuo, Malcolm S Ross, Mayu Yunokawa, M S Johnson, Hiroko Machida, Kohei Omatsu, Merieme Klobocista, Dwight D Im, Shinya Satoh, Tsukasa Baba
    Abstract:

    Abstract Objective To examine survival after recurrence (SAR) among women with recurrent uterine Carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. Methods We retrospectively examined 148 women with recurrent uterine Carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine Carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. Results There were 71 (48.0%) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5% versus 34.8%, P P =0.02). When stratified by disease-free interval, women with a disease-free interval ≥6months who received a taxane/platinum doublet had a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens (61.9% versus 40.0%, HR 0.46, 95% CI 0.28 to 0.75, P =0.002); conversely, in women with a disease-free interval versus 18.4%, HR 0.80, 95% CI 0.33 to 1.90, P =0.61). Among women who received a taxane/platinum doublet as adjuvant chemotherapy, re-treatment with taxane/platinum doublet as salvage chemotherapy remained beneficial (2-year SAR rate, 62.1% versus 39.7%, HR 0.40, 95% CI 0.18 to 0.86, P =0.019). Conclusion Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine Carcinosarcoma, especially for those who had a disease-free interval of ≥6months.

  • tumor characteristics and survival outcomes of women with tamoxifen related uterine Carcinosarcoma
    Gynecologic Oncology, 2017
    Co-Authors: Koji Matsuo, Malcolm S Ross, Mayu Yunokawa, Shinya Satoh, Tsukasa Baba, Stephen H Bush, Erin A Blake, Tadao Takano, Yutaka Ueda, Masako Shida
    Abstract:

    Abstract Objective To examine tumor characteristics and survival outcome of women with uterine Carcinosarcoma who had a history of tamoxifen use. Methods This is a multicenter retrospective study examining stage I–IV uterine Carcinosarcoma cases based on history of tamoxifen use. Patient demographics, tumor characteristics, treatment pattern, and survival outcomes were compared between tamoxifen users and non-users. Results Sixty-six cases of tamoxifen-related uterine Carcinosarcoma were compared to 1009 cases with no history of tamoxifen use. Tamoxifen users were more likely to be older (mean age, 69 versus 64, P versus 12.7%, P versus 29.9%) and a lower risk of stage IVB disease (7.8% versus 16.0%) compared to tamoxifen-unrelated Carcinosarcoma ( P =0.034). Deep myometrial tumor invasion was less common in uterine Carcinosarcoma related to tamoxifen use (28.3% versus 48.8%, P =0.002). On univariate analysis, tamoxifen use was not associated with progression-free survival (5-year rates 44.5% versus 46.8%, P =0.48) and disease-specific survival (64.0% versus 59.1%, P =0.39). After adjusting for age, past history of malignancy, stage, residual disease status at surgery, and postoperative treatment patterns, tamoxifen use was not associated with progression-free survival (adjusted-hazard ratio 0.86, 95% confidence interval 0.50 to 1.50, P =0.60) and disease-specific survival (adjusted-hazard ratio 0.68, 95% confidence interval 0.36 to 1.29, P =0.24). Conclusion Our study suggests that tamoxifen-related uterine Carcinosarcoma may have favorable tumor characteristics but have comparable stage-specific survival outcomes compared to tamoxifen-unrelated uterine Carcinosarcoma.

Koji Matsuo - One of the best experts on this subject based on the ideXlab platform.

  • salvage chemotherapy with taxane and platinum for women with recurrent uterine Carcinosarcoma
    Gynecologic Oncology, 2017
    Co-Authors: Koji Matsuo, Malcolm S Ross, Mayu Yunokawa, M S Johnson, Hiroko Machida, Kohei Omatsu, Merieme Klobocista, Dwight D Im, Shinya Satoh, Tsukasa Baba
    Abstract:

    Abstract Objective To examine survival after recurrence (SAR) among women with recurrent uterine Carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. Methods We retrospectively examined 148 women with recurrent uterine Carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine Carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. Results There were 71 (48.0%) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5% versus 34.8%, P P =0.02). When stratified by disease-free interval, women with a disease-free interval ≥6months who received a taxane/platinum doublet had a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens (61.9% versus 40.0%, HR 0.46, 95% CI 0.28 to 0.75, P =0.002); conversely, in women with a disease-free interval versus 18.4%, HR 0.80, 95% CI 0.33 to 1.90, P =0.61). Among women who received a taxane/platinum doublet as adjuvant chemotherapy, re-treatment with taxane/platinum doublet as salvage chemotherapy remained beneficial (2-year SAR rate, 62.1% versus 39.7%, HR 0.40, 95% CI 0.18 to 0.86, P =0.019). Conclusion Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine Carcinosarcoma, especially for those who had a disease-free interval of ≥6months.

  • tumor characteristics and survival outcomes of women with tamoxifen related uterine Carcinosarcoma
    Gynecologic Oncology, 2017
    Co-Authors: Koji Matsuo, Malcolm S Ross, Mayu Yunokawa, Shinya Satoh, Tsukasa Baba, Stephen H Bush, Erin A Blake, Tadao Takano, Yutaka Ueda, Masako Shida
    Abstract:

    Abstract Objective To examine tumor characteristics and survival outcome of women with uterine Carcinosarcoma who had a history of tamoxifen use. Methods This is a multicenter retrospective study examining stage I–IV uterine Carcinosarcoma cases based on history of tamoxifen use. Patient demographics, tumor characteristics, treatment pattern, and survival outcomes were compared between tamoxifen users and non-users. Results Sixty-six cases of tamoxifen-related uterine Carcinosarcoma were compared to 1009 cases with no history of tamoxifen use. Tamoxifen users were more likely to be older (mean age, 69 versus 64, P versus 12.7%, P versus 29.9%) and a lower risk of stage IVB disease (7.8% versus 16.0%) compared to tamoxifen-unrelated Carcinosarcoma ( P =0.034). Deep myometrial tumor invasion was less common in uterine Carcinosarcoma related to tamoxifen use (28.3% versus 48.8%, P =0.002). On univariate analysis, tamoxifen use was not associated with progression-free survival (5-year rates 44.5% versus 46.8%, P =0.48) and disease-specific survival (64.0% versus 59.1%, P =0.39). After adjusting for age, past history of malignancy, stage, residual disease status at surgery, and postoperative treatment patterns, tamoxifen use was not associated with progression-free survival (adjusted-hazard ratio 0.86, 95% confidence interval 0.50 to 1.50, P =0.60) and disease-specific survival (adjusted-hazard ratio 0.68, 95% confidence interval 0.36 to 1.29, P =0.24). Conclusion Our study suggests that tamoxifen-related uterine Carcinosarcoma may have favorable tumor characteristics but have comparable stage-specific survival outcomes compared to tamoxifen-unrelated uterine Carcinosarcoma.

David G Bostwick - One of the best experts on this subject based on the ideXlab platform.

  • Carcinosarcoma and sarcomatoid carcinoma of the bladder clinicopathological study of 41 cases
    The Journal of Urology, 1998
    Co-Authors: Antonio Lopezbeltran, Anna Pacelli, H J Rothenberg, Peter C Wollan, Horst Zincke, Michael L Blute, David G Bostwick
    Abstract:

    AbstractPurpose: Carcinosarcoma of the bladder is a rare neoplasm characterized by an intimate admixture of carcinoma and malignant soft tissue neoplasm. The clinical usefulness of separating Carcinosarcoma (carcinoma with sarcomatous component) from sarcomatoid carcinoma (carcinoma with spindle cell carcinomatous component) is uncertain, and it comprises the subject of this report.Materials and Methods: We reviewed the clinical and pathological records of 10 men and 5 women a mean of 66 years old with Carcinosarcoma, and 21 men and 5 women a mean of 66.5 years old with sarcomatoid carcinoma of the bladder, as documented in the files of the Mayo Clinic between 1936 and 1995.Results: Of the 15 patients in the Carcinosarcoma group 9 had urothelial carcinoma, small cell carcinoma, 3 had squamous cell carcinoma and 2 had more than 1 type. The sarcomatous component included chondrosarcoma in 3 cases, leiomyosarcoma in 3, malignant fibrous histiocytoma in 3, osteosarcoma in 2, fibrosarcoma in 1, rhabdomyosarcom...

  • Carcinosarcoma of the prostate report of 21 cases
    Cancer, 1995
    Co-Authors: Paul Dundore, John C Cheville, Antonio G Nascimento, George M Farrow, David G Bostwick
    Abstract:

    Background. Carcinosarcoma of the prostate is an unusual malignancy characterized by adenocarcinoma intimately admixed with sarcoma. Methods. The authors reviewed the clinical and pathologic findings of 21 cases of Carcinosarcoma of the prostate from the files of the Mayo Clinic. Results. Patient age ranged from 50 to 89 years (mean, 68 years). Ten patients (48%) had a previous diagnosis of prostatic acinar adenocarcinoma 2–73 months (mean, 33 months) before the diagnosis of Carcinosarcoma, 8 of whom had received androgen deprivation therapy and/ or radiation therapy in the interim. The Gleason score of adenocarcinoma ranged from 7 to 10 (mean, 9; median, 9). The sarcomas consisted of osteosarcoma (13), leiomyosarcoma (5), fibrosarcoma (1), malignant fibrous histiocytoma (1), and rhabdomyosarcoma (1), and the grade of the sarcoma component ranged from 2 to 4 (mean, 4; median, 4). Adenocarcinoma was the dominant histologic pattern in 7 cases and sarcoma in 14. Immunohistochemical staining revealed cytoplasmic reactivity for prostate specific antigen or keratin in 16 of 16 cases in the adenocarcinoma component. The sarcoma component was positive for vimentin in 16 of 16 cases, actin in 8 of 16 (focal in 2), S-100 protein in 2 of 16, and desmin in 1 of 16. At the time of diagnosis of Carcinosarcoma, 11 patients had metastases, including 4 with metastatic adenocarcinoma before the diagnosis of Carcinosarcoma. Treatment varied, and nonsurgical therapy was ineffective. Sites of metastases included lung (10 cases), bone (7), brain (4), liver (1), and peritoneum (1). Follow-up ranged from 1 to 107 months after the diagnosis of Carcinosarcoma (mean, 34 months; median, 10 months). Mean time to tumor progression was 23 months (range, 1-96 months; median, 18 months). Eighteen patients died of Carcinosarcoma from 2 to 107 months (mean, 34 months; median, 9.5 months) after diagnosis. Five-year survival was 41%, and 7-year survival was 14%. Progression and survival were not affected by histologic pattern. Conclusions. Carcinosarcoma of the prostate is an aggressive malignancy, regardless of histologic type. Cancer 1995;76:1035–42.

Malcolm S Ross - One of the best experts on this subject based on the ideXlab platform.

  • salvage chemotherapy with taxane and platinum for women with recurrent uterine Carcinosarcoma
    Gynecologic Oncology, 2017
    Co-Authors: Koji Matsuo, Malcolm S Ross, Mayu Yunokawa, M S Johnson, Hiroko Machida, Kohei Omatsu, Merieme Klobocista, Dwight D Im, Shinya Satoh, Tsukasa Baba
    Abstract:

    Abstract Objective To examine survival after recurrence (SAR) among women with recurrent uterine Carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. Methods We retrospectively examined 148 women with recurrent uterine Carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine Carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. Results There were 71 (48.0%) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5% versus 34.8%, P P =0.02). When stratified by disease-free interval, women with a disease-free interval ≥6months who received a taxane/platinum doublet had a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens (61.9% versus 40.0%, HR 0.46, 95% CI 0.28 to 0.75, P =0.002); conversely, in women with a disease-free interval versus 18.4%, HR 0.80, 95% CI 0.33 to 1.90, P =0.61). Among women who received a taxane/platinum doublet as adjuvant chemotherapy, re-treatment with taxane/platinum doublet as salvage chemotherapy remained beneficial (2-year SAR rate, 62.1% versus 39.7%, HR 0.40, 95% CI 0.18 to 0.86, P =0.019). Conclusion Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine Carcinosarcoma, especially for those who had a disease-free interval of ≥6months.

  • tumor characteristics and survival outcomes of women with tamoxifen related uterine Carcinosarcoma
    Gynecologic Oncology, 2017
    Co-Authors: Koji Matsuo, Malcolm S Ross, Mayu Yunokawa, Shinya Satoh, Tsukasa Baba, Stephen H Bush, Erin A Blake, Tadao Takano, Yutaka Ueda, Masako Shida
    Abstract:

    Abstract Objective To examine tumor characteristics and survival outcome of women with uterine Carcinosarcoma who had a history of tamoxifen use. Methods This is a multicenter retrospective study examining stage I–IV uterine Carcinosarcoma cases based on history of tamoxifen use. Patient demographics, tumor characteristics, treatment pattern, and survival outcomes were compared between tamoxifen users and non-users. Results Sixty-six cases of tamoxifen-related uterine Carcinosarcoma were compared to 1009 cases with no history of tamoxifen use. Tamoxifen users were more likely to be older (mean age, 69 versus 64, P versus 12.7%, P versus 29.9%) and a lower risk of stage IVB disease (7.8% versus 16.0%) compared to tamoxifen-unrelated Carcinosarcoma ( P =0.034). Deep myometrial tumor invasion was less common in uterine Carcinosarcoma related to tamoxifen use (28.3% versus 48.8%, P =0.002). On univariate analysis, tamoxifen use was not associated with progression-free survival (5-year rates 44.5% versus 46.8%, P =0.48) and disease-specific survival (64.0% versus 59.1%, P =0.39). After adjusting for age, past history of malignancy, stage, residual disease status at surgery, and postoperative treatment patterns, tamoxifen use was not associated with progression-free survival (adjusted-hazard ratio 0.86, 95% confidence interval 0.50 to 1.50, P =0.60) and disease-specific survival (adjusted-hazard ratio 0.68, 95% confidence interval 0.36 to 1.29, P =0.24). Conclusion Our study suggests that tamoxifen-related uterine Carcinosarcoma may have favorable tumor characteristics but have comparable stage-specific survival outcomes compared to tamoxifen-unrelated uterine Carcinosarcoma.

Shinya Satoh - One of the best experts on this subject based on the ideXlab platform.

  • salvage chemotherapy with taxane and platinum for women with recurrent uterine Carcinosarcoma
    Gynecologic Oncology, 2017
    Co-Authors: Koji Matsuo, Malcolm S Ross, Mayu Yunokawa, M S Johnson, Hiroko Machida, Kohei Omatsu, Merieme Klobocista, Dwight D Im, Shinya Satoh, Tsukasa Baba
    Abstract:

    Abstract Objective To examine survival after recurrence (SAR) among women with recurrent uterine Carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. Methods We retrospectively examined 148 women with recurrent uterine Carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine Carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. Results There were 71 (48.0%) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5% versus 34.8%, P P =0.02). When stratified by disease-free interval, women with a disease-free interval ≥6months who received a taxane/platinum doublet had a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens (61.9% versus 40.0%, HR 0.46, 95% CI 0.28 to 0.75, P =0.002); conversely, in women with a disease-free interval versus 18.4%, HR 0.80, 95% CI 0.33 to 1.90, P =0.61). Among women who received a taxane/platinum doublet as adjuvant chemotherapy, re-treatment with taxane/platinum doublet as salvage chemotherapy remained beneficial (2-year SAR rate, 62.1% versus 39.7%, HR 0.40, 95% CI 0.18 to 0.86, P =0.019). Conclusion Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine Carcinosarcoma, especially for those who had a disease-free interval of ≥6months.

  • tumor characteristics and survival outcomes of women with tamoxifen related uterine Carcinosarcoma
    Gynecologic Oncology, 2017
    Co-Authors: Koji Matsuo, Malcolm S Ross, Mayu Yunokawa, Shinya Satoh, Tsukasa Baba, Stephen H Bush, Erin A Blake, Tadao Takano, Yutaka Ueda, Masako Shida
    Abstract:

    Abstract Objective To examine tumor characteristics and survival outcome of women with uterine Carcinosarcoma who had a history of tamoxifen use. Methods This is a multicenter retrospective study examining stage I–IV uterine Carcinosarcoma cases based on history of tamoxifen use. Patient demographics, tumor characteristics, treatment pattern, and survival outcomes were compared between tamoxifen users and non-users. Results Sixty-six cases of tamoxifen-related uterine Carcinosarcoma were compared to 1009 cases with no history of tamoxifen use. Tamoxifen users were more likely to be older (mean age, 69 versus 64, P versus 12.7%, P versus 29.9%) and a lower risk of stage IVB disease (7.8% versus 16.0%) compared to tamoxifen-unrelated Carcinosarcoma ( P =0.034). Deep myometrial tumor invasion was less common in uterine Carcinosarcoma related to tamoxifen use (28.3% versus 48.8%, P =0.002). On univariate analysis, tamoxifen use was not associated with progression-free survival (5-year rates 44.5% versus 46.8%, P =0.48) and disease-specific survival (64.0% versus 59.1%, P =0.39). After adjusting for age, past history of malignancy, stage, residual disease status at surgery, and postoperative treatment patterns, tamoxifen use was not associated with progression-free survival (adjusted-hazard ratio 0.86, 95% confidence interval 0.50 to 1.50, P =0.60) and disease-specific survival (adjusted-hazard ratio 0.68, 95% confidence interval 0.36 to 1.29, P =0.24). Conclusion Our study suggests that tamoxifen-related uterine Carcinosarcoma may have favorable tumor characteristics but have comparable stage-specific survival outcomes compared to tamoxifen-unrelated uterine Carcinosarcoma.